Novel Parameters for the Assessment of LFLG AS Peri-TAVI Procedure

  • Research type

    Research Study

  • Full title

    Utility of Novel Echocardiographic and Invasive Haemodynamic Measurements in the assessment of patients with Low Flow Low Gradient Aortic Stenosis undergoing TAVI; A pilot study.

  • IRAS ID

    303172

  • Contact name

    James Cotton

  • Contact email

    jamescotton@nhs.net

  • Sponsor organisation

    The Royal Wolverhampton NHS Trust

  • Clinicaltrials.gov Identifier

    NCT05196815

  • Clinicaltrials.gov Identifier

    N/A, N/A

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    Trans-Catheter Aortic Valve implantation (TAVI) is an established therapy for the treatment of patients with symptomatic narrowing of the aortic valve (Aortic Stenosis). It involves the implantation of a new valve via a tube inserted into an artery at the top of the leg, removing the need for surgical opening of the chest. It is associated with a reduction in symptoms and improved survival in selected patients.

    Patients with reduced heart function prior to TAVI represent a difficult group to treat. These patients are at higher procedural risk compared to those with good heart pump function. In some, treatment leads to complications and/or little or no improvement in symptoms or heart pump function.

    It is important that we try to predict the outcome of TAVI in this high-risk population for clinical and health economic reasons.

    The current technique for assessing the likelihood of improvement of heart pump function following TAVI (contractile reserve on stress echocardiography) has been shown not to predict outcome well.

    This pilot study of ten patients will involve the assessment of a variety of novel markers of heart strength (contractility) at the time of the TAVI, to see whether any predict how well patients with weak hearts will respond.

    At their routine stress echocardiogram (cardiac ultrasound) prior to the TAVI, participants will have some additional markers of muscle strength measured.
    During the TAVI procedure, additional measurements relating to cardiac contractility will be taken using a drug to speed up the the heart(dobutamine) and a pressure wire. Echocardiograms will be undertaken following TAVI and at 3 months to assess the outcome of the procedure.

    This pilot study will be used to inform the feasibility of a larger, multi-centre trial powered to assess the value of the measured novel techniques to yield prognostic information regarding outcomes in this patient cohort.

  • REC name

    South West - Cornwall & Plymouth Research Ethics Committee

  • REC reference

    22/SW/0012

  • Date of REC Opinion

    24 Jan 2022

  • REC opinion

    Favourable Opinion